Screener
TransMedics Group, Inc. TMDX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206453
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research, development and clinical trials | 24,879 | 17,160 |
| Selling, general and administrative | 62,985 | 43,625 |
| Total operating expenses | 87,864 | 60,785 |
| Income from operations | 13,297 | 27,443 |
| Other income (expense): | ||
| Interest expense | (7,170) | (3,461) |
| Interest income and other income (expense), net | 2,358 | 2,694 |
| Total other expense, net | (4,812) | (767) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is TransMedics Group, Inc.'s operating income?
- TransMedics Group, Inc. (TMDX) reported operating income of $13.3M in Q1 2026.
- How has TransMedics Group, Inc.'s operating income changed year-over-year?
- TransMedics Group, Inc.'s operating income decreased by 51.5% year-over-year, from $27.44M to $13.3M.
- What is the long-term trend for TransMedics Group, Inc.'s operating income?
- Over 4 years (2021 to 2025), TransMedics Group, Inc.'s operating income has grown at a 28.8% compound annual growth rate (CAGR), from -$39.43M to $108.58M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about TransMedics Group, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude